Guggenheim Issues Positive Forecast for Twist Bioscience (NASDAQ:TWST) Stock Price

Twist Bioscience (NASDAQ:TWST) had its price objective upped by Guggenheim from $50.00 to $55.00 in a research note released on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities analysts have also recently weighed in on the stock. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research note on Friday. Evercore lifted their target price on Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a report on Tuesday, February 3rd. Robert W. Baird set a $50.00 target price on Twist Bioscience in a research note on Tuesday, February 3rd. Finally, Barclays raised their price target on Twist Bioscience from $39.00 to $50.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Twist Bioscience has a consensus rating of “Moderate Buy” and a consensus price target of $46.50.

Twist Bioscience Stock Performance

TWST stock opened at $43.26 on Monday. The company has a 50 day moving average price of $46.51 and a 200 day moving average price of $36.78. Twist Bioscience has a fifty-two week low of $23.30 and a fifty-two week high of $57.88. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.78 and a quick ratio of 3.37. The stock has a market capitalization of $2.65 billion, a PE ratio of -33.80 and a beta of 2.23.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The firm had revenue of $103.70 million during the quarter, compared to the consensus estimate of $100.32 million. Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The company’s revenue for the quarter was up 16.9% on a year-over-year basis. Analysts forecast that Twist Bioscience will post -2.12 EPS for the current year.

Insider Buying and Selling at Twist Bioscience

In related news, CFO Adam Laponis sold 7,000 shares of the business’s stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $50.00, for a total value of $350,000.00. Following the sale, the chief financial officer directly owned 130,031 shares of the company’s stock, valued at approximately $6,501,550. The trade was a 5.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Robert Chess sold 10,000 shares of the company’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $47.00, for a total transaction of $470,000.00. Following the completion of the transaction, the director directly owned 21,084 shares of the company’s stock, valued at approximately $990,948. The trade was a 32.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 48,190 shares of company stock valued at $2,234,695 over the last quarter. 3.08% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TWST. Royal Bank of Canada lifted its stake in Twist Bioscience by 11.8% in the 1st quarter. Royal Bank of Canada now owns 40,373 shares of the company’s stock valued at $1,585,000 after acquiring an additional 4,254 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Twist Bioscience by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company’s stock worth $2,765,000 after acquiring an additional 3,181 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Twist Bioscience by 4.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock worth $36,629,000 after acquiring an additional 37,577 shares in the last quarter. Intech Investment Management LLC grew its stake in shares of Twist Bioscience by 18.9% during the 1st quarter. Intech Investment Management LLC now owns 28,917 shares of the company’s stock worth $1,135,000 after acquiring an additional 4,591 shares in the last quarter. Finally, Legal & General Group Plc raised its holdings in shares of Twist Bioscience by 22.0% in the second quarter. Legal & General Group Plc now owns 110,286 shares of the company’s stock valued at $4,057,000 after purchasing an additional 19,915 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.